Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 26 articles:
HTML format
Text format



Single Articles


    July 2018
  1. BARNETT R
    Liver cirrhosis.
    Lancet. 2018;392:275.
    PubMed     Text format    


    May 2018
  2. GARCIA-TSAO G
    Long-term albumin in cirrhosis: is it the ANSWER?
    Lancet. 2018 May 31. pii: S0140-6736(18)30948.
    PubMed     Text format    


  3. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Lancet. 2018 May 31. pii: S0140-6736(18)30840.
    PubMed     Text format     Abstract available


    March 2018
  4. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
    NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
    PubMed     Text format     Abstract available


    February 2018
  5. KUDO M, Finn RS, Qin S, Han KH, et al
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
    PubMed     Text format     Abstract available


    January 2018
  6. PATTEN DA, Shetty S
    Chronic liver disease: scavenger hunt for novel therapies.
    Lancet. 2018;391:104-105.
    PubMed     Text format    


  7. FORNER A, Reig M, Bruix J
    Hepatocellular carcinoma.
    Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
    PubMed     Text format     Abstract available


    April 2017
  8. WORNS MA, Galle PR
    Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
    PubMed     Text format    


  9. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
    PubMed     Text format     Abstract available


    February 2017
  10. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Text format     Abstract available


    January 2017
  11. SOTIROPOULOS GC, Machairas N, Kostakis ID, Kouraklis G, et al
    The struggle for intensive care coverage after hepatic resections: the Greek reality.
    Lancet. 2017;389:364-365.
    PubMed     Text format    


    December 2016
  12. BRUIX J, Qin S, Merle P, Granito A, et al
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32453.
    PubMed     Text format     Abstract available


  13. NAULT JC
    The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32480.
    PubMed     Text format    


    November 2016
  14. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    


    October 2016
  15. MAO X, Yan C, Li Y, Lin Y, et al
    Pharmacological mechanisms of Euphorbia Pekinensis and Glycyrrhiza acting on hepatocellular carcinoma ascites: a preclinical study.
    Lancet. 2016;388 Suppl 1:S93.
    PubMed     Text format     Abstract available


  16. YANG X, Yu D, Ren Y, Wei J, et al
    EPB41, a novel hepatoma susceptibility gene dysregulated by c-Myc: an integrative functional genomics study.
    Lancet. 2016;388 Suppl 1:S89.
    PubMed     Text format     Abstract available


  17. ZHANG YF, Shi M, Guo RP
    A novel risk score (MCCT) to guide decision for treatment of advanced hepatocellular carcinoma with transarterial chemoembolisation: a derivation and validation study.
    Lancet. 2016;388 Suppl 1:S35.
    PubMed     Text format     Abstract available


    August 2016
  18. POWELL LW, Seckington RC, Deugnier Y
    Haemochromatosis.
    Lancet. 2016;388:706-16.
    PubMed     Text format     Abstract available


    June 2016
  19. NEWSOME PN, Armstrong MJ, Gaunt P
    Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
    Lancet. 2016;387:2379.
    PubMed     Text format    


  20. DALE A, Hartley P, Heneghan C
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378.
    PubMed     Text format    


  21. GABORIT B, Darmon P, Ancel P, Dutour A, et al
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378-9.
    PubMed     Text format    


    May 2016
  22. BRIERLEY R, Bosurgi R
    Gastroenterology and hepatology: a call for papers.
    Lancet. 2016;387:1889-1890.
    PubMed     Text format    


    March 2016
  23. CORRIGAN M, Alrubaiy L, China L
    Hepatology training in the UK.
    Lancet. 2016;387:1055.
    PubMed     Text format    


    November 2015
  24. WONG VW, Wong GL
    A LEAN treatment for non-alcoholic steatohepatitis.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00982.
    PubMed     Text format    


  25. ARMSTRONG MJ, Gaunt P, Aithal GP, Barton D, et al
    Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00803.
    PubMed     Text format     Abstract available


    October 2015
  26. BERNAL W, Jalan R, Quaglia A, Simpson K, et al
    Acute-on-chronic liver failure.
    Lancet. 2015;386:1576-87.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: